Can metagenomic next-generation sequencing identify the pathogens responsible for culture-negative prosthetic joint infection?

Table 3 Treatment factors and results of the EA group

Case	Tsukayama type	Surgical protocol	Antibiotic regimen		Reason for culture-negative	Follow-up (month)	Subsequent intervention	Antibiotic costs (Yuan)
Case	Tsukayama type	Surgical protocol	Intravenous	Oral	Reason for culture-negative	Follow-up (month)	Subsequent intervention	Antibiotic costs (Yuan)
EA-1	IV	Two-stage revision	Vancomycin Ceftazidime	Levofloxacin Rifampicin	Unknown	34	–	8587.82
EA-2	IV	Two-stage revision	Vancomycin Meropenem	Levofloxacin Rifampicin	Unknown	34	I&D	39,572.64
EA-3	IV	Two-stage revision	Vancomycin Ceftazidime	Levofloxacin Rifampicin	Unknown	38	–	16,837.93
EA-4	IV	Two-stage revision	Vancomycin Ceftazidime	Levofloxacin Rifampicin	Unknown	37	–	6697.8
EA-5	II	I&D	Vancomycin Levofloxacin	Levofloxacin Rifampicin	Prior use of antibiotics	43	I&D	23,050.38
EA-6	II	I&D	Vancomycin Meropenem	Levofloxacin Rifampicin	Prior use of antibiotics	40	Suppressive antibiotic therapy	30,235.4
EA-7	IV	One-stage revision	Vancomycin Ceftazidime	Levofloxacin Rifampicin	Prior use of antibiotics	37	–	3236.38
EA-8	II	I&D	Vancomycin Ceftazidime	Levofloxacin Rifampicin	Unknown	42	–	9051.3
EA-9	II	I&D	Vancomycin Meropenem	Levofloxacin Rifampicin	Prior use of antibiotics	41	–	45,297.16
EA-10	II	I&D	Vancomycin Ceftazidime	Levofloxacin Rifampicin	Unknown	44	–	6583.4
EA-11	IV	Two-stage revision	Vancomycin Moxifloxacin	Levofloxacin Rifampicin	Unknown	38	–	13,756.7
EA-12	IV	Two-stage revision	Vancomycin Ceftazidime	Levofloxacin Rifampicin	Prior use of antibiotics	41	I&D	39,113.54

ISSN: 1471-2334